Opportunity Information: Apply for SOURCES SOUGHT NOTICE 2018
USAID/Tanzania issued a sources sought notice in 2018 for an activity called Sustainable Access for Expanded Voluntary Medical Male Circumcision (VMMC) Services, abbreviated as SAFE. The opportunity was positioned as a local-partner activity, meaning USAID was specifically looking for Tanzanian entities to be the implementing partner. The geographic focus covered five regions: Iringa, Njombe, Morogoro, Tabora, and Singida. The overall public health purpose was HIV prevention, using voluntary medical male circumcision as a proven biomedical intervention to reduce the risk of new HIV infections.
SAFE was framed around expanding access to high-quality VMMC services for boys and men, with an emphasis on services that are safe, voluntary, and clinically sound. The description highlights "high quality lifelong biomedical interventions," which in the VMMC context generally implies not only performing circumcisions to standard medical protocols, but also ensuring the surrounding package of care is strong enough to protect clients over the long term. In practice, this typically includes HIV testing services offered according to national policy, risk-reduction counseling, screening for sexually transmitted infections, referral linkages for HIV treatment and other care when needed, post-operative follow-up, management of adverse events, and clear education on wound care and the period of abstinence required for proper healing. The mention of "young boys and men" signals that the target population includes adolescents as well as adults, which often requires youth-friendly service delivery approaches and careful attention to consent and safeguarding requirements for minors.
As a sources sought notice, this posting functioned more like a market research and partner-identification step than a final grant competition announcement. The listing identifies the instrument type broadly as "Other" under a discretionary opportunity, and it does not provide an award ceiling or a specific number of expected awards in the public summary. The original closing date for responses was November 15, 2018, and the notice was created on November 2, 2018. The assistance listing references CFDA 98.001, which is commonly associated with USAID foreign assistance.
In plain terms, USAID/Tanzania was signaling an intent to support a locally led effort that would increase the reach and sustainability of VMMC services in the named regions, with the ultimate goal of preventing new HIV infections. The brief public synopsis points interested Tanzanian organizations to the attachment for full details, which would typically include the scope of work, the kind of organizational capacity USAID wanted to see (clinical service delivery experience, quality assurance, supply chain and commodity management, data reporting and monitoring, community mobilization, and coordination with regional and national health authorities), and instructions for how local entities should respond to the sources sought request.Apply for SOURCES SOUGHT NOTICE 2018
- The Tanzania USAID-Dar es Salaam in the health sector is offering a public funding opportunity titled "Sustainable Access for Expanded Voluntary Medical Male circumcision (VMMC) Services (SAFE)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 98.001.
- This funding opportunity was created on 2018-11-02.
- Applicants must submit their applications by 2018-11-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQ): USAID/Tanzania SAFE VMMC Sources Sought (2018)
What is the SAFE activity?
SAFE stands for Sustainable Access for Expanded Voluntary Medical Male Circumcision (VMMC) Services. It was described as an HIV prevention activity focused on expanding access to high-quality VMMC services for boys and men.
Who issued this opportunity?
The notice was issued by USAID/Tanzania.
What type of posting is this (grant competition or something else)?
This was a sources sought notice. That means it functioned as a market research and partner-identification step rather than a final grant competition announcement.
What was USAID/Tanzania trying to learn or accomplish through the sources sought?
Based on the summary, USAID/Tanzania was seeking to identify potential implementing partners and understand the availability and capacity of Tanzanian entities to carry out a locally led activity to expand and sustain VMMC services in the specified regions.
Was the SAFE activity intended to be locally led?
Yes. The opportunity was positioned as a local-partner activity, with USAID specifically looking for Tanzanian entities to be the implementing partner.
Which geographic areas were included?
The geographic focus covered five regions in Tanzania: Iringa, Njombe, Morogoro, Tabora, and Singida.
What public health goal was SAFE designed to support?
The overall purpose was HIV prevention, using voluntary medical male circumcision (VMMC) as a proven biomedical intervention intended to reduce the risk of new HIV infections.
Who were the intended beneficiaries or target clients?
The description refers to "young boys and men," indicating the target population includes adolescents as well as adults.
What does “voluntary” mean in the context of VMMC services described here?
The summary emphasizes services that are safe and voluntary. In this context, “voluntary” signals that clients choose to receive the service, and service delivery should be consistent with ethical and clinical standards for voluntary uptake.
What does “high-quality” VMMC service mean in this notice?
The notice emphasizes expanding access to high-quality VMMC services that are safe and clinically sound. In the VMMC context described, this generally implies performing circumcisions according to standard medical protocols and ensuring the surrounding package of care is strong enough to protect clients over the long term.
What “package of care” elements are typically included alongside VMMC, based on the description?
The synopsis suggests a broader lifelong biomedical intervention approach. In practice, this typically includes HIV testing services offered according to national policy, risk-reduction counseling, screening for sexually transmitted infections, referral linkages for HIV treatment and other care when needed, post-operative follow-up, management of adverse events, and clear education on wound care and the period of abstinence required for proper healing.
Does the notice mention youth-friendly services or protections for minors?
It does not lay out specific requirements in the public summary, but by referencing "young boys and men," it signals that adolescents are included. The description notes that serving adolescents often requires youth-friendly approaches and careful attention to consent and safeguarding requirements for minors.
What kind of organizations was USAID interested in hearing from?
The opportunity was aimed at Tanzanian entities as potential implementing partners. The summary indicates that the full details were in an attachment, which would typically describe desired organizational capacity such as clinical service delivery experience, quality assurance, supply chain and commodity management, data reporting and monitoring, community mobilization, and coordination with regional and national health authorities.
What was the instrument type for this opportunity?
The listing identified the instrument type broadly as "Other" under a discretionary opportunity.
Was an award amount (ceiling) provided?
No award ceiling is provided in the public summary described.
Did the notice state how many awards USAID expected to make?
No. The public summary did not provide a specific number of expected awards.
What were the key dates for the sources sought notice?
The notice was created on November 2, 2018, and the original closing date for responses was November 15, 2018.
What assistance listing (CFDA) was referenced?
The assistance listing referenced CFDA 98.001, which is commonly associated with USAID foreign assistance.
Where were interested organizations directed to find the full details?
The public synopsis pointed interested Tanzanian organizations to the attachment for full details, which would typically include the scope of work and instructions for how to respond to the sources sought request.
What is the basic takeaway of this notice in plain language?
USAID/Tanzania was signaling an intent to support a locally led effort to increase the reach and sustainability of VMMC services in Iringa, Njombe, Morogoro, Tabora, and Singida, with the ultimate goal of preventing new HIV infections.
Browse more opportunities from the same category: Health
Next opportunity: Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03 - Clinical Trial Not Allowed)
Previous opportunity: Middle Entiat Gray Project
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for SOURCES SOUGHT NOTICE 2018
Applicants also applied for:
Applicants who have applied for this opportunity (SOURCES SOUGHT NOTICE 2018) also looked into and applied for these:
| Funding Opportunity |
|---|
| Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) Apply for RFA AG 20 004 Funding Number: RFA AG 20 004 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Investigator Initiated Research in Computational Genomics and Data Science (R43/R44 Clinical Trial Not Allowed) Apply for PAR 19 061 Funding Number: PAR 19 061 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed) Apply for PA 19 067 Funding Number: PA 19 067 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single-Cell Multi-Omics of HIV Persistence (R01 Clinical Trial Not Allowed) Apply for RFA AI 18 053 Funding Number: RFA AI 18 053 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed) Apply for PA 19 066 Funding Number: PA 19 066 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed) Apply for PA 19 068 Funding Number: PA 19 068 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed) Apply for RFA DE 19 008 Funding Number: RFA DE 19 008 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed) Apply for RFA DE 19 009 Funding Number: RFA DE 19 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Medications Development for the Treatment of Alcohol Use Disorder (U01 Clinical Trial Optional) Apply for RFA AA 19 005 Funding Number: RFA AA 19 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) Apply for PAR 19 070 Funding Number: PAR 19 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed) Apply for PAR 19 071 Funding Number: PAR 19 071 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 18 057 Funding Number: RFA AI 18 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R21 Clinical Trial Optional) Apply for RFA MH 19 411 Funding Number: RFA MH 19 411 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R34 Clinical Trial Required) Apply for RFA MH 19 410 Funding Number: RFA MH 19 410 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R01 Clinical Trial Optional) Apply for RFA MH 19 412 Funding Number: RFA MH 19 412 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44 Clinical Trial Not Allowed) Apply for PA 19 076 Funding Number: PA 19 076 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Development of Rapid Fungal Diagnostics (R21 Clinical Trial Not Allowed) Apply for PA 19 081 Funding Number: PA 19 081 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed) Apply for PAR 19 079 Funding Number: PAR 19 079 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R01 Clinical Trial Not Allowed) Apply for PA 19 082 Funding Number: PA 19 082 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel approaches to understand, prevent, treat, and diagnose coccidioidomycosis (Valley Fever) and other select endemic fungal infections (R21 Clinical Trial Not Allowed) Apply for PA 19 083 Funding Number: PA 19 083 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "SOURCES SOUGHT NOTICE 2018", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.